Navigation Links
BioCryst to Present at the 11th Annual BIO CEO & Investor Conference

BIRMINGHAM, Ala., Feb. 2 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, will present a corporate update at the 11th Annual BIO CEO & Investor Conference on Monday, February 9, 2009 at 11:30 a.m. Eastern Time. The conference will be held February 9-10, 2009 in New York.

A link to a live audio Web cast of the presentation may be accessed on the BioCryst Web site at The presentation will be archived for 14 days.

About BioCryst

BioCryst is an integrated biopharmaceutical company utilizing crystallography and structure-based drug design to develop a deep pipeline of novel therapeutics targeting major illnesses. BioCryst is currently advancing investigational new drugs discovered in-house in late-stage clinical trials for influenza and lymphoma. In addition, the Company has a pre-clinical portfolio of novel compounds, directed against infectious, cardiovascular, and autoimmune disease targets, to create long-term sustainable value. The Company's strategic alliances with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings Ltd. validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company's Web site at

Forward-looking statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates, that our projected burn rate may not be consistent with our expectations, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (filed November 28, 2008), Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.


SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009
2. BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
3. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
4. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
5. BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007
6. Interleukin Genetics to Present at G-2 Reports Molecular Diagnostic Conference
7. Prescription Drugs: Good Medicine - Bad Behavior; Science Matters Program Explores the Rise in Prescription Drug Abuse Presented by the California Science Center
8. Inverness Medical Innovations to Present at the 2009 UBS Global Healthcare Services Conference on February 10, 2009
9. eResearchTechnology, Inc. to Present at the UBS Global Healthcare Services Conference on February 10, 2009
10. Triple-S Management Corporation to Present at UBS Global Healthcare Services Conference
11. International Medical Interpreter Association Appoints IMIA State Representatives
Post Your Comments:
(Date:11/30/2015)... Madeira Beach, FL (PRWEB) , ... November 30, ... ... issue of Consumer Reports magazine, quoted Michael Hansen, Ph.D., a senior scientist at ... exposure, and even more so for a child’s exposure limits. , The original ...
(Date:11/30/2015)... ... November 30, 2015 , ... Medicalis, a ... Radiology Society of North America (RSNA) annual meeting, being held November 29 – ... 2014. Throughout 2015, the company has completed installations for Integrated Delivery Network ...
(Date:11/30/2015)... ... ... It’s inevitable that everyone will experience death in his or her lifetime. ... lives among us. It is your perspective, however, that determines how you view death ... T Sky understands that she may see death more frequently than most. As she ...
(Date:11/30/2015)... ... ... The successful filing of an Investigational New Drug application (IND) is a ... key industry segment, Regis Technologies has decided to sponsor and participate in an XTalks-hosted ... , Federal law does not allow new drugs to cross state lines until it ...
(Date:11/30/2015)... ... ... Scott Newman MD, FACS of New York’s Advanced Plastic ... the New York City area to utilize the new, non-invasive SculpSure™ Laser System ... for fat loss in the abdomen, flanks, and other areas that is completely ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 30, 2015  PTS Diagnostics, the U.S.-based manufacturer of ... analyzers, A1CNow ® systems, and PTS Detect™ cotinine ... patents that will propel the company into the mHealth ... Europe . The technology is a system ... on smartphones and tablets, and uses test strip technology ...
(Date:11/30/2015)... NASHUA, N.H. , Nov. 30, 2015 /PRNewswire/ ... today that it will feature its latest solutions ... the early identification of cancer at the Radiological ... in Chicago from November ... showcase recent product advances including iReveal®, an automated ...
(Date:11/30/2015)... -- Hanger, Inc. (NYSE: HGR ) (the "Company") today ... its previously announced consent solicitation (as amended and restated, ... amount 7⅛% Senior Notes due 2018 (the "Notes") to ... pursuant to the Consent Solicitation, (ii) the proposed increased ... date of the Consent Solicitation.    ...
Breaking Medicine Technology: